Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Liposarcoma · Prostate Cancer · Advanced Breast Cancer · NSCLC (Non-small Cell Lung Cancer) · Colorectal Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 430 (planned)
- Started
- Sep 23, 2020
- Main results expected
- Oct 7, 2029
- Fully finished
- Oct 7, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with dose limiting toxicities in the Dose Escalation or De-escalation Portion
Measured over: At the end of Cycle 1 (each cycle is 28 days)
Incidence of clinically significant AEs
Measured over: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Incidence of clinically significant laboratory assessments
Measured over: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Incidence of clinically significant abnormal vital and ECG parameters
Measured over: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Maximal Plasma Concentration (Cmax) of PF-07220060 given with and without food
Measured over: Cycle 1 (each cycle is 28 days)
Time to Maximum Plasma Concentration (Tmax) of PF-07220060 given with and without food
Measured over: Cycle 1 (each cycle is 28 days)
Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point (AUClast) of PF-07220060 given with and without food
Measured over: Cycle 1 (each cycle is 28 days)
Maximal Plasma Concentration (Cmax) of Midazolam with and without PF-07220060
Measured over: Cycle 1 (each cycle is 28 days)
Time to Maximum Plasma Concentration (Tmax) of Midazolam with and without PF-07220060
Measured over: Cycle 1 (each cycle is 28 days)
Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Timepoint (AUClast) of Midazolam with and without PF-07220060
Measured over: Cycle 1 (each cycle is 28 days)
Steady State Maximal Concentration (Cmax,ss) of PF-07220060
Measured over: Cycle 1 (each cycle is 28 days)
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of PF-07220060
Measured over: Cycle 1 (each cycle is 28 days)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of PF-07220060
Measured over: Cycle 1 (each cycle is 28 days)
Steady State Minimum Plasma Concentration (Cmin,ss) of PF-07220060
Measured over: Cycle 1 (each cycle is 28 days)
Steady State Maximal Concentration (Cmax,ss) of Giredestrant
Measured over: Cycle 1 (each cycle is 28 days)
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Giredestrant
Measured over: Cycle 1 (each cycle is 28 days)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of Giredestrant
Measured over: Cycle 1 (each cycle is 28 days)
Steady State Minimum Plasma Concentration (Cmin,ss) of Giredestrant
Measured over: Cycle 1 (each cycle is 28 days)
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["referencesModule"]}
Trial ID NCT04557449 · record last updated 2026-10-28 · checked 2026-11-09 15:36 UTC